Lupron is an injectable medication used to suppress sex hormones, and it treats a surprisingly wide range of conditions: advanced prostate cancer, endometriosis, uterine fibroids, early puberty in children, and infertility as part of IVF protocols. The common thread is that all these conditions respond to lowering estrogen or testosterone levels in the body.
How Lupron Works
Lupron works by hijacking the brain’s hormone signaling system. It mimics a natural hormone called GnRH, which tells the pituitary gland to release the signals that drive testosterone and estrogen production. When you first receive Lupron, it actually causes a temporary surge in sex hormones. But because the drug continuously stimulates the pituitary (rather than pulsing naturally), the receptors become overwhelmed and shut down within about two to three weeks. The result is a dramatic drop in sex hormone levels, sometimes described as a form of chemical castration.
This two-phase effect matters. The initial hormone surge can temporarily worsen symptoms, particularly in prostate cancer patients, where testosterone levels can rise roughly 65% above baseline within the first three days. Testosterone typically stays elevated for 7 to 15 days before falling to very low levels. Despite how alarming this sounds, reviews of the medical literature have not found strong evidence that this short flare causes meaningful disease progression, even in men with widespread cancer.
Prostate Cancer
The most common use of Lupron is treating advanced prostate cancer. Prostate tumors are fueled by testosterone, so driving testosterone to near-zero levels slows or stops tumor growth. Lupron is FDA-approved as a long-acting depot injection, meaning the medication is released slowly from a single shot over weeks or months. Formulations range from a monthly injection to one that lasts six months, so treatment schedules can be tailored to what works best for each patient. This is often a long-term therapy, sometimes lasting years.
Endometriosis
In women with endometriosis, tissue similar to the uterine lining grows outside the uterus, causing pain during periods, pain during sex, and chronic pelvic discomfort. By suppressing estrogen, Lupron shrinks these misplaced tissue implants and reduces inflammation. Clinical studies showed it was comparable to other established treatments in relieving pelvic pain, painful periods, and painful intercourse, while also reducing the size of endometrial implants visible during surgery.
Treatment for endometriosis is typically limited to six months because of side effects from prolonged estrogen suppression, particularly bone loss. However, some patients with severe, chronic pelvic pain have been treated for much longer periods when combined with “add-back” hormone therapy, a strategy that replaces just enough estrogen and progesterone to protect bones and reduce hot flashes without reactivating endometrial growths.
Uterine Fibroids
Lupron can shrink uterine fibroids, the noncancerous growths that develop in or on the uterus. It’s typically used as a short-term treatment before surgery rather than a permanent solution, since fibroids tend to regrow once the medication stops. In clinical trials, uterine volume decreased by about 41% and fibroid volume shrank by 37% during treatment. The average fibroid diameter went from 5.6 cm to 4.7 cm. Shrinking fibroids before surgery can make the procedure less invasive, reduce blood loss, and sometimes allow a less extensive operation.
As with endometriosis, treatment duration for fibroids is generally capped at three to six months.
Central Precocious Puberty
Lupron has a pediatric formulation designed specifically for children who enter puberty abnormally early, a condition called central precocious puberty (CPP). By suppressing the hormonal signals driving premature sexual development, the medication pauses puberty until a more appropriate age. This helps protect the child’s final adult height, since early puberty causes growth plates to close sooner, and also addresses the psychological and social challenges of developing years ahead of peers.
The pediatric version is approved for children one year of age and older. Diagnosis requires specific testing to confirm that early puberty is being driven by the brain’s hormonal signaling rather than another cause. Once treatment starts, hormone levels are monitored within the first couple of months and periodically afterward to make sure suppression is working.
IVF and Fertility Treatment
Lupron plays a different role in fertility treatment. During IVF, doctors need precise control over when and how eggs mature. Lupron prevents the body from ovulating on its own, which would ruin an egg retrieval cycle. It takes roughly 10 days for the drug to fully suppress the pituitary gland. This suppression also synchronizes the growth of multiple follicles, making the ovaries more responsive to stimulation medications and reducing the chance that one follicle races ahead of the others.
Two main protocols use Lupron in IVF. The “long Lupron” protocol starts injections around day 21 of the previous menstrual cycle and is typically recommended for patients under 35 with poor egg quality or a history of mediocre response to ovarian stimulation. The “flare” or “microdose” protocol starts Lupron during the stimulation phase itself and is more often used for women 38 and older or those with a prior poor response. In this protocol, the initial hormone surge Lupron causes is actually used to the patient’s advantage, providing an extra boost of natural stimulation to the ovaries before suppression kicks in.
Side Effects and Bone Health
Because Lupron works by suppressing sex hormones, its side effects largely mirror menopause in women and low testosterone in men. Hot flashes are the most common complaint across all patient groups. Women may also experience vaginal dryness, mood changes, headaches, and decreased sex drive. Men commonly experience fatigue, hot flashes, reduced libido, and weight changes.
The most significant long-term concern is bone loss. In women treated for endometriosis, vertebral bone density dropped an average of 3.2% after six months of treatment. In fibroid patients treated for three months, the decrease was about 2.7%. Some of this bone loss may not be fully reversible, which is why treatment courses are kept short and bone density is measured before any repeat courses are considered.
Patients with additional risk factors for bone thinning, such as smoking, heavy alcohol use, a strong family history of osteoporosis, or use of certain other medications like corticosteroids or anticonvulsants, face a higher risk. For these patients, add-back therapy with a small dose of hormones plus calcium supplementation can significantly reduce bone loss while maintaining the therapeutic benefit of Lupron. Clinical studies confirm that this combination approach effectively protects bone mineral density during treatment.
Who Should Not Use Lupron
Lupron is contraindicated during pregnancy because suppressing reproductive hormones can harm a developing fetus. It should also not be used by women with unexplained abnormal uterine bleeding, since the cause needs to be identified before treatment. Anyone with a known allergy to Lupron or similar GnRH medications should avoid it. The injection must be given by or under the supervision of a healthcare provider, and the different formulation strengths are not interchangeable because each is designed for a specific dosing interval.